EP0313274A1 - Enzymatisches Bestimmungsverfahren - Google Patents

Enzymatisches Bestimmungsverfahren Download PDF

Info

Publication number
EP0313274A1
EP0313274A1 EP88309624A EP88309624A EP0313274A1 EP 0313274 A1 EP0313274 A1 EP 0313274A1 EP 88309624 A EP88309624 A EP 88309624A EP 88309624 A EP88309624 A EP 88309624A EP 0313274 A1 EP0313274 A1 EP 0313274A1
Authority
EP
European Patent Office
Prior art keywords
enzyme
substrate
product
analyte
bound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP88309624A
Other languages
English (en)
French (fr)
Inventor
Ramadan Arabi Abuknesha
Hugh Peter Bennetto
Jeremy Richard Mason
Philip Giles Nugent
John Laing Stirling
Christopher Frank Thurston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Alcan International Ltd Canada
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcan International Ltd Canada, Kings College London filed Critical Alcan International Ltd Canada
Publication of EP0313274A1 publication Critical patent/EP0313274A1/de
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)

Definitions

  • Competition assays such as immunoassays and immunometric assays, are widely used in clinical chemistry. They afford a level of specificity and sensitivity which is difficult, or impossible, to match by other analytical procedures. There is a need, however, to increase the sensitivity of such assays still further, for two reasons. Firstly, some analytes of interest are present at extremely low concentrations. Secondly, more sensitive assays can commonly be employed to detect higher concentrations of analytes more quickly. Attempts have been made to maximise assay sensitivity by employing radiolabelled, fluorescent or chemiluminescent reagents, but ideal combinations of sensitivity, reproducibility and convenience have not been achieved for all applications.
  • An alternative strategy to improve assay sensitivity is to employ an amplification step, such that a product which may be generated in not more than stoichiometric amounts to the analyte, generates the production of a significantly higher concentration of a second product which is then observed.
  • the use of enzymes for this purpose has been widely described in the literature. By repeatedly acting as catalysts, enzymes can achieve amplification by factors of hundreds or thousands.
  • A.Johannsson et al. describes an assay for TSH.
  • a first catalytic step involves the dephosphorylation of NADP to produce NAD, which catalytically activates a specific redox cycle to generate an intensely coloured compound which is observed.
  • the method has the disadvantage of using esoteric unstable enzymes, and of involving NADP/NAD, so that it cannot be used with samples containing these materials.
  • Yolken R.H. (Rev. Infec. Dis., 4, (1982) 35-68) describes an immunoassay with complement mediated amplification. The method is dependent on non-­specific complement cascade activation steps, and the components are difficult to isolate.
  • EPA 75379 (Syva) and EPA 152254 (Du Pont) both describe immunoassays which involve binding two enzymes to a solid phase, one in proportion to the analyte concentration, the product of one enzyme being the substrate of the other.
  • EPA 180327 (Amoco) describes an immunosassay system involving enzymes in which a reaction product can exist in a different (fluid) phase from the substrate.
  • the assay method of the present invention uses at least one, and in its preferred forms two or even more, enzyme amplification steps. In its preferred forms also, the method requires use of reagents which are readily obtained or prepared and which are stable for useful periods.
  • the invention provides a method of assaying for an analyte in a sample, by the use of a first enzyme, and a first substrate on which the first enzyme can act to generate a first product, which method comprises the steps:-
  • the nature of the analyte is not critical.
  • the analyte may for example be a hapten or an antigen or an antibody, such as a hormone, a steroid, a drug or drug metabolite, a protein, a nucleic acid, a vitamin or a polysaccharide.
  • the nature of the sample is also not critical.
  • the sample may be a biological fluid, such as serum, plasma, urine or milk.
  • the function of the first enzyme is to act on the first substrate so as to produce a distinctive first product.
  • the first enzyme may be an oxidoreductase, a transferase, a lyase, an isomerase, a ligase or a hydrolase.
  • the glycosidases, phosphatases, sulphatases, esterases and lipases can be found within this last class of enzymes.
  • the function of the first substrate is to be acted on by the first enzyme so as to generate a distinctive first product. Therefore, the choice of the first substrate is dictated by the choice of the first enzyme.
  • a key feature of the invention is this action of the first enzyme on the first substrate to reveal a first product having antigenic determinants (or other binding domains) for binding to an antibody (or other specific binder) which may be labelled with a (component of a) signal generating system.
  • a principal function of the labelled specific binder is to bind specifically to the first product.
  • the first product and the specific binder may form an immune pair, with one being the antigen and the other the antibody; or these two may constitute some other specific binding system, such as the avidin or streptavidin-biotin system. It is important that the labelled specific binder reacts, not significantly and preferably not at all, with the first substrate. Thus, the first product needs to be distinctive in the sense that it is recognized for binding purposes by the specific binder as distinct from the first substrate.
  • the label of the labelled specific binder may be any label conventionally used for detection in competition assays.
  • the label may be a radioisotope, a fluorescent material or a member of an enzyme system to generate a luminescent or electrochemical or colorimetric signal.
  • the label is a second enzyme, which may be the same as, or more preferably different from, the first enzyme, for by this means a second amplification stage can be introduced into the assay as will be described in more detail below.
  • the first step of the method involves subjecting the sample to an assay procedure to generate the first enzyme in a predetermined state in a concentration related to the concentration of the analyte in the sample.
  • the enzyme is attached to the analyte itself or to one of the assay reagents, generally either an analogue of the analyte or a specific binder (e.g. an antibody) to the analyte.
  • the attachment of enzymes to reagents of this kind is well described in the literature.
  • the predetermined state in which the enzyme is generated may conveniently be in solution (in which state it may readily be separated from enzyme bound to a solid surface); or alternatively bound to a solid surface (in which state it may readily be separated from enzyme in solution).
  • step a) of the method of the invention will now be described by way of example. A skilled reader will have no difficulty in concocting others. In these examples, it will be assumed for simplicity that the analyte is antigenic and that its specific binder is an antibody, although, as explained above, the invention is not so limited.
  • the reagents are an analyte analogue, in a matrix-bound form; and an antibody to the analyte, labelled with an enzyme, in solution.
  • the enzyme-labelled antibody in solution is contacted with the matrix-bound analyte analogue, to which it becomes bound. Excess solution is removed by washing.
  • the liquid sample is incubated with the matrix-bound analyte analogue/antibody complex.
  • Analyte in the sample competes with matrix-­bound analyte analogue for binding to the antibody.
  • an analyte/enzyme-labelled antibody complex in a concentration directly proportional to the concentration of the analyte in the sample. This solution is then used for the next stage of the method.
  • the reagents are a matrix-bound antibody to the analyte; and an enzyme-labelled analyte analogue in solution.
  • the enzyme-labelled analyte analogue in solution is contacted with the matrix-bound antibody, and becomes bound thereto. Excess solution is removed by washing. Then the sample is incubated with the matrix-bound antibody/labelled analyte analogue complex. Analyte in the sample competes with labelled analyte analogue for binding to the antibody, and displaces some of the labelled analyte analogue into solution.
  • the resulting solution which contains enzyme-labelled analyte analogue in a concentration directly proportional to the analyte concentration in the sample, can be used for step b).
  • the solution can be discarded and the solid phase used instead.
  • the reagents are the same as in A, but the order of reaction is different.
  • the sample is incubated with the solution of enzyme-­labelled antibody.
  • the resulting mixture is contacted with the matrix-bound analyte analogue.
  • sample and the enzyme-labelled antibody solution could have been added to the matrix-­bound analyte analogue at the same time and the whole procedure performed in a single incubation.
  • the reagents are the same as in B, but the order of reaction is different.
  • the sample is incubated with the enzyme-labelled analyte analogue solution.
  • the resulting mixture is contacted with the matrix-bound antibody.
  • sample and the enzyme-labelled analyte analogue solution could have been added to the matrix-bound antibody at the same time, and the whole procedure performed in a single incubation.
  • the reagents are a matrix-­bound first antibody to the analyte; and an enzyme-­labelled second antibody to the analyte in solution.
  • the method involves incubating these two reagents with the sample, in one or two stages and with any order of mixing. The result is a sandwich of matrix-(first antibody)-(analyte)-(enzyme-labelled second antibody).
  • the amount of enzyme-labelled second antibody on the solid phase is directly proportional to the amount of analyte in the sample.
  • the amount of enzyme-­labelled second antibody in solution is inversely proportional to the amount of analyte in the sample. Either the solution or the solid phase can be used for step b).
  • a function of the procedure of step a) is to separate the enzyme-labelled reagent into two fractions. However, it is not necessary that one of these be in the liquid phase while the other is matrix-­bound. Indeed, physical separation of the two fractions is not always necessary. It is possible to devise a system in which the enzyme in one fraction, but not the other, has been inactivated. Other systems include the following.
  • Step b) of the method of the invention involves contacting the first enzyme in the predetermined state, i.e. the chosen fraction of the enzyme-labelled reagent, with an amount of a first substrate under conditions to generate a first product.
  • the first enzyme is in solution, and in order to facilitate the subsequent steps of the method, it will usually be convenient to provide the substrate in a form bound to a solid matrix or to some other material by means of which it may be readily separated from the supernatant liquid.
  • the first substrate may comprise the first product masked by a group which is removed by action of the enzyme to reveal the first product.
  • Immobilized and immobilizable substrates for this purpose can be prepared according to well established chemical methods.
  • the general structure of such substrates can be represented as follows:- X-O-A-L-M where X is a glycosyl, phosphate, diphosphate, sulphate or other residue chosen in relation to the enzyme being used; O is usually, but not necessarily, a hydroxy function, but may also be for example an amino, carboxyl or sulphydryl group; A may be for example an aromatic nucleus, part of a heterocyclic centre, peptide or steroid, revealed by removal of X by the enzyme; L is a chemical bridge formed by a bifunctional coupling agent such as glutaraldehyde, dihydrazide, amino acid, 6-aminohexanoic acid, diimidate; and M may be a macromolecular carrier such as a carrier protein, soluble polysaccharide or enzyme; or a solid support such as a glass, plastic, polymer, ceramic or paper
  • glycosidic residues into the hydroxyl functions of A structures may be performed according to the general principles of the Koenigs-­Knorr reaction. Tetra-O-acetyl-alpha-D-­galactopyranosyl bromide may be reacted with the hydroxyl-A under appropriate conditions. Isolation of the final product can be effected by standard chemical procedures using acid/alkaline extraction steps as well as column chromatography on silica gel. The preparation of first substrate, both in solution and in matrix-bound form, is described below in Examples 1 - 3, and EPA 28332 also provides relevant information.
  • An advantage of providing the first substrate in a matrix-bound form is that steps a) and b) of the assay method can be performed in a single vessel without the need for decanting or washing.
  • a disadvantage is that the kinetics of reaction between the matrix-bound substrate and the first enzyme may be rather slow. In cases where this proves a problem, it may be preferred to provide the first substrate in solution. In that case, the first enzyme may be generated either in solution or in a matrix-bound form. It is often more convenient to generate the first enzyme in a matrix-­bound form.
  • the first enzyme in the predetermined state is incubated with the first substrate to reveal the first product.
  • This is the first amplification stage of the method.
  • the amount of the first substrate and the time and other conditions of incubation need to be chosen together to ensure that the first product is revealed at a concentration which is not only amplified but also related to the concentration of the analyte in the starting sample. In other words, reaction between the first enzyme and the first substrate must not be allowed to go to completion, so that there is left at the end of the step a mixture of the first substrate and the first product.
  • step c) of the method the first product is contacted with a labelled specific binder under conditions to cause them to become bound together, and in this way the amount, or the presence, of the first product is determined. How this is done is not material to the invention. Many different techniques are available and described in the literature. When the first substrate has been provided in a matrix-bound form, this step usually involves incubating the labelled specific binder with a mixture of the first product and unreacted residual first substrate. As noted above, it is important to the success of the method that the labelled specific binder should bind, not significantly and preferably not at all, to the first substrate. Design of the first product and first substrate for this purpose is to some extent a matter of trial and error, albeit in accordance with known principles. Using a polyclonal antibody as the specific binder, we have achieved cross reactivities below 0.018%, and expect that this figure would be reduced much further by the use of a monoclonal antibody.
  • step c When the first substrate is provided in solution, with the result that the first product is generated in solution, it is preferable to separate the two before going on to step c). This may be done by the use of excess of a matrix-bound antibody (or other specific binder) to bind to the antigenic determinants (or other binding sites) of the first product that have been revealed by action of the first enzyme on the first substrate.
  • the supernatant liquid comprising residual first substrate is decanted and the solid phase washed.
  • a labelled reagent is caused to become bound to the matrix-bound first product.
  • step c) incubation it is normally necessary to separate that portion of the labelled specific binder that has become bound to the first product, from that portion not so bound. If the first product is immobilised on a solid matrix, such separation is readily achieved by decanting and washing. If the first product is generated in solution, then some other means of separation may need to be found. Alternatively, for some label systems physical separation may not be necessary, for example, label bound (or not bound) to the first product may be masked or inactivated in some way.
  • this determination involves a second amplification stage.
  • one molecule of bound second enzyme acts on many molecules of a second substrate in the solution to generate many molecules of a second product which is observed, e.g. by luminescence, fluorescence or colour change.
  • the second substrate needs to be provided in excess, and incubation with the bound enzyme needs to be continued under predetermined conditions for a predetermined time.
  • Step d) of the method involves using the result of step c) to determine the concentration, or the presence, of the analyte in the sample. This is generally done by means of a standard curve. Standard samples containing known concentrations of analayte spanning the expected range of the unknowns are subjected to the method. The results are used to plot a graph of signal intensity against analyte concentration. After the signal intensity of an unknown sample has been determined, the analyte concentration in that sample can simply be read off the graph.
  • Fluorescein amine (1g, 2.9 mmoles) and succinic anhydride (400 mg, 4 mmoles) were refluxed in 50ml THF, for 4 hours. After removal of the solvent, 100ml of 0.5M HCl was added to the residue. After 1 hour on ice, 200ml ethyl acetate was added in order to dissolve the heavy precipitate which had appeared.
  • the organic layer was washed with acid, with water, dried over Na2SO4, and reduced in volume until the fluorescein amine-hemisuccinate (FAHS) began to precipitate. Precipitation was allowed to continue in the cold, after which the product was washed with cold ethyl acetate and dried under vacuum.
  • FHS fluorescein amine-hemisuccinate
  • Fluorescein amine hemisuccinate 500mg, 1.1 mmole
  • acetobromo-alpha-D-galactose 2g, 4.9 mmole
  • the reaction was monitored by TLC in ethyl acetate: MeOH (80:20).
  • the di-galactosyl fluorescein amine-­hemisuccinate was examined by scanning spectrophotometry in order to identify the wavelength of its maximum absorbance. Using stock solutions of known concentration, a preliminary molar extinction coefficient for the aglycone at 490nm was determined of approx. 38,000. Inspection under U.V. illumination showed a very pronounced difference between the fluorescence of the aglycone and the much less fluorescent di-galactoside.
  • Substrate 200 ⁇ l; 4mM in 50mM Tris buffer pH 7.3, 0.1M NaCl, ImM MgCl2
  • E. coli beta-galactosidase 100 ⁇ l; 0.28U
  • the reaction was stopped by the addition of ice cold 0.5M CO3/HCO3 buffer pH 9.5 (0.5ml) and the absorbance of the reaction mixture read at 490nm.
  • the slope of the line generated indicated that 74 pmoles of product was produced per minute under these conditions.
  • the di-galactosyl-FAHS showed clear activity as a beta-galactosidase substrate
  • the cross-reactivity of this substrate with respect to its aglycone was assessed using the 3H-fluorescein tracer. The results showed that while the anti-fluorescein antiserum was easily able to recognise and bind the aglycone, it was less easily able to recognise and bind the intact substrate.
  • a 45 fold molar excess of FAHS was required to inhibit the binding of the 3H-tracer by a suitable diluted anti-fluorescein antiserum by 50%, while over the range tested, the di-galactosyl-FAHS was unable to inhibit this binding.
  • the cross reactivity of the substrate was therefore less than 0.45% of that exhibited by the aglycone.
  • AH-sepharose 4B One gram of AH-sepharose 4B was swollen, washed and suspended in 10ml of 0.01M phosphate buffer, pH 6.8. To the suspension was added 209mg substrate from Example 1 and 400mg CMC, and the mixture was mixed with rolling for 24 hours. A further 200mg of CMC was added, and the reaction was allowed to proceed for a further 24 hours. The gel was washed using the usual conditions of low and high pH, and then stored in PBS. It had a pronounced yellow colour. To test whether the substrate on the sepharose was available for enzymic hydrolysis, a series of 20 ⁇ l aliquots of a 50% suspension of substrate-sepharose were incubated with or without beta-galactosidase, overnight. RIA performed in the same tubes showed that the test samples gave a 27% binding of tracer while the control samples bound 45% of the tracer. This result indicated clearly that the substrate on AH-sepharose was available for hydrolysis by
  • Nitro-fluorescein was prepared according to standard methods. The methyl ester was prepared by refluxing nitrofluorescein in excess methanol in the presence of 1% conc. H2SO4.
  • the galactose was introduced into the remaining free hydroxy function of nitrofluorescein-methyl ester using tetra-acetyl-bromogalactose in the presence of silver carbonate (catalyst) and calcium sulphate (internal desiccant) in benzene-tetrahydrofuran mixture.
  • nitrofluorescein methyl ester was prepared using dimethyl sulphate and 0.IN NaOH according to standard methylation procedure. Removal of the ester gave mono-methoxy nitrofluorescein.
  • the galactose was introduced as given above.
  • the wells of the second plate (Plate 2) were coated overnight at 4°C with either BSA alone (100 ⁇ l; 1 mg/ml in coating buffer) or BSA-coumarin- ⁇ -galactoside (100 ⁇ l;1 mg/ml in coating buffer). Immediately before use, the plate was washed three times in coating buffer, and a further once with ⁇ -galactosidase assay buffer (0.1M sodium phosphate buffer pH 7.1, 0.1M NaCl, 10 mM MgCl2).
  • ⁇ -galactosidase assay buffer 0.1M sodium phosphate buffer pH 7.1, 0.1M NaCl, 10 mM MgCl2.
  • the assay was performed as follows. To each well of Plate-1 containing ouabain-fetuin antigen was added digoxin solution (1 ng/ml - 1 mg/ml in 150 ⁇ l PBS). After 1 hour at 37°C, the contents of each individual well were mixed, and a sample of the supernatant from each (100 ⁇ l) transferred to a well of Plate-2 containing immobilised BSA-coumarin- ⁇ -galactoside (and 50 ⁇ l ⁇ -galactosidase assay buffer). PBS (100 ⁇ l) was placed in wells of Plate-2 containing immobilised BSA (and 50 ⁇ l ⁇ -galactosidase assay buffer).
  • Figure 3 shows the activity of bound alkaline phosphatase-conjugated anti-coumarin IgG to immobilised coumarin residues following their exposure by hydrolysis of immobilised coumarin- ⁇ -galactoside by displaced ⁇ -galactosidase-conjugated anti-digoxin IgG.
  • the binding of alkaline phosphatase-anti-coumarin to BSA alone was less than 5% of maximal binding to BSA-­coumarin.
  • the binding of the conjugate to unhydrolysed substrate was approximately 29% of maximal bnding. This value was subtracted from all others before plotting. Assays were performed in duplicate.
  • Dextran T40 was oxidised by sodium periodate to produce aldehyde functions; diamino hexane was introduced followed by reduction with sodium borohydride to stabilize the link.
  • Coumarin-galactose and estradiol were introduced into the dextran-6-amino hexane via active esters of their derivatives. The active esters were added sequentially to the dextran to a ratio of 5:1 substrate to estradiol. The reaction is shown in Figure 4.
  • the double conjugate was dialysed and chromato­graphed on Sephadex G50.
  • the fractions containing the dextran showed fluorescence (faint, indicative of the coumarin substrate).
  • a solution of the resulting dextran-substrate (1 mg/ml) in ⁇ -galactosidase assay buffer was prepared, and to this was added anti-coumarin IgG (12 ⁇ l suitably diluted anti-coumarin IgG in washing buffer/ 120 ⁇ l dextran-substrate) to block any exposed sites which may be present as impurities. (This step is not obligatory to the method). The mixture was incubated for 1 hour at 37°C.
  • the plate was then incubated at room temperature for 2 hours, and excess conjugate removed from the wells by washing, as above.
  • Digoxin solutions (1 ng-1 ⁇ g/ml in PBS) or PBS alone, were prepared, and 100 ⁇ l of each added to the wells of an ELISA plate displaying solid-phase ouabain-­anti-digoxin conjugate. After 60 minutes at room temperature, with agitation, 100 ⁇ l from each well was either assayed using oNp-galactoside in a standard reference assay, or added to 100 ⁇ l dextran-substrate.
  • alkaline phosphatase substrate solution 100 ⁇ l; 6 mM pNp-phosphatase in phosphatase assay buffer was added to each well.
  • the absorbance of the product solutions were read after 5, 10 and 15 minutes, against the substrate blank (100 ⁇ l alkaline phosphatase substrate solution incubated over the same period).
  • Galactosyl-coumarin-3-acetic acid was prepared according to standard chemical procedure. The cross reaction was estimated by radio-immunoassay using 3H-­labelled 7-hydroxy coumarin-3-acetic acid derivative and rabbit anti-7-hydroxy coumarin-3-acetic acid.
  • the low cross reaction indicates the large difference in affinities of the coumarin and the galactosyl-coumarin for the anti-coumarin antibodies.
  • Conjugates of coumarin-3-acetic acid and 17 ⁇ -­estradiol-3-carboxymethyl ether with 1,8-diamino octane as an arm was prepared and purified by standard organic chemistry procedures. A soluble version of the conjugate was also prepared (see Figure 6). Galactose was introduced on to the 7-hydroxy function of the coumarin in the conjugate by standard methods.
  • the immune activities of the conjugate and the substrate conjugate were analysed by standard ELISA procedure.
  • Microtitre plates were coated with rabbit anti-­coumarin. A range of concentrations of the conjugate and the substrate were added to the coated wells, allowed to react, and after washing anti-estradiol antibody labelled with alkaline phosphatase was added to the wells and was allowed to react.
  • a range of dilutions of E.Coli - ⁇ -galactosidase were prepared from a stock solution (about 1mg/ml of a commercial preparation).
  • the standard assay was carried out as follows:- In the microtitre plate wells, 10 ⁇ l of ⁇ -­galactosidase were added to 100 ⁇ l of pNp-galactoside and after 90 minutes the reaction was terminated by 100 ⁇ l stopping buffer and the absorbance levels were read.
  • the amplified assay was carried out as follows:- In the microtitre plate wells, 10 ⁇ l of the enzyme were added to 100 ⁇ l of 50 ⁇ g/ml of galactosyl-­coumarin diamino octane-estradiol 3 CME conjugate. After 20 minutes incubation, the reaction products were diluted 1/256 and 100 ⁇ l were transferred to microtitre plate wells coated with anti-coumarin. After 20 minutes the plate was washed and anti-estradiol-alkaline phosphatase was added and allowed to react for 20 minutes before washing and phosphatase activity measurements at from 10 to 30 minutes.
  • the graph ( Figure 7) shows the absorbances against ⁇ -gal dilutions.
  • the amplified assay is about 1000 times more sensitive than the standard assay (see above). (Not taking into account the dilution factor of the product prior to the introduction to the anti-­coumarin antibody coated wells).
  • Sheep anti 17-OH-Progesterone was coupled to particles by the standard CNBr activation method.
  • 17-OH-Progesterone-3-carboxymethyl oxime was prepared and conjugated to E.Coli ⁇ -galactosidase (commercial preparation) by standard methods.
  • a competitive enzyme immunoassay was established (free standard analyte competes with the enzyme-­labelled analyte for the antibody on the magnetizable particles).
  • the activity of the bound fraction of tracer was measured using the standard pNp-galactoside or the amplification procedure using galactosyl-­coumarin-diamino octane-estradiol 3 CME as a first substrate and magnetizable particles coupled anti-­coumarin preparation to capture product 1 (or a fraction of it).
  • the levels of the captured product 1 were estimated by the use of anti-estradiol alkaline phosphatase and conjugate and a phosphatase activity measurement using pNp-phosphate.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP88309624A 1987-10-22 1988-10-14 Enzymatisches Bestimmungsverfahren Withdrawn EP0313274A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878724764A GB8724764D0 (en) 1987-10-22 1987-10-22 Enzyme assay method
GB8724764 1987-10-22

Publications (1)

Publication Number Publication Date
EP0313274A1 true EP0313274A1 (de) 1989-04-26

Family

ID=10625729

Family Applications (1)

Application Number Title Priority Date Filing Date
EP88309624A Withdrawn EP0313274A1 (de) 1987-10-22 1988-10-14 Enzymatisches Bestimmungsverfahren

Country Status (9)

Country Link
EP (1) EP0313274A1 (de)
JP (1) JPH01295165A (de)
KR (1) KR890006828A (de)
CN (1) CN1034273A (de)
AU (1) AU2409088A (de)
BR (1) BR8805933A (de)
DK (1) DK582888A (de)
GB (1) GB8724764D0 (de)
NO (1) NO884705L (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0347256A2 (de) * 1988-06-17 1989-12-20 Tosoh Corporation Verfahren zum Nachweis einer Substanz in einer Probe
EP0538053A1 (de) * 1991-10-18 1993-04-21 Gec-Marconi Limited Trennung und Analyse
WO1993011432A1 (en) * 1991-11-27 1993-06-10 Gec-Marconi Limited Reagent system and method of analysis
WO2001079528A1 (en) * 2000-04-13 2001-10-25 3M Innovative Properties Company Bacteria and bacteriophage detection using immobilized enzyme substrates
US7297354B2 (en) 2000-04-26 2007-11-20 Land O'lakes, Inc. Protein material

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028332A1 (de) * 1979-10-23 1981-05-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferon-markierte Protein- und Polypeptidkonjugate und N-substituierte 7-beta-Galactosylcumarin-3-carboxamide
EP0075379A1 (de) * 1981-09-18 1983-03-30 Syva Company Kompetitives Immunverfahren auf einer Oberfläche
EP0152254A2 (de) * 1984-02-06 1985-08-21 E.I. Du Pont De Nemours And Company Immunotest mit chromogenischer Träger unter Verwendung von markierten Komplementbestandteilen
EP0180327A1 (de) * 1984-09-27 1986-05-07 Amoco Corporation Bestimmungsmethode unter Einbeziehung einer Phasentrennung und Testsatz hierfür

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028332A1 (de) * 1979-10-23 1981-05-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferon-markierte Protein- und Polypeptidkonjugate und N-substituierte 7-beta-Galactosylcumarin-3-carboxamide
EP0075379A1 (de) * 1981-09-18 1983-03-30 Syva Company Kompetitives Immunverfahren auf einer Oberfläche
EP0152254A2 (de) * 1984-02-06 1985-08-21 E.I. Du Pont De Nemours And Company Immunotest mit chromogenischer Träger unter Verwendung von markierten Komplementbestandteilen
EP0180327A1 (de) * 1984-09-27 1986-05-07 Amoco Corporation Bestimmungsmethode unter Einbeziehung einer Phasentrennung und Testsatz hierfür

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0347256A2 (de) * 1988-06-17 1989-12-20 Tosoh Corporation Verfahren zum Nachweis einer Substanz in einer Probe
EP0347256A3 (de) * 1988-06-17 1990-07-11 Tosoh Corporation Verfahren zum Nachweis einer Substanz in einer Probe
EP0538053A1 (de) * 1991-10-18 1993-04-21 Gec-Marconi Limited Trennung und Analyse
US6225043B1 (en) 1991-10-18 2001-05-01 Gec-Marconi Limited Separation and analysis
WO1993011432A1 (en) * 1991-11-27 1993-06-10 Gec-Marconi Limited Reagent system and method of analysis
WO2001079528A1 (en) * 2000-04-13 2001-10-25 3M Innovative Properties Company Bacteria and bacteriophage detection using immobilized enzyme substrates
US6436661B1 (en) 2000-04-13 2002-08-20 3M Innovative Properties Company Bacteria and bacteriophage detection using immobilized enzyme substrates
US6833251B2 (en) 2000-04-13 2004-12-21 3M Innovative Properties Company Bacteria detection using immobilized enzyme substrates
US7297354B2 (en) 2000-04-26 2007-11-20 Land O'lakes, Inc. Protein material

Also Published As

Publication number Publication date
AU2409088A (en) 1989-04-27
GB8724764D0 (en) 1987-11-25
NO884705L (no) 1989-04-24
DK582888A (da) 1989-04-23
CN1034273A (zh) 1989-07-26
BR8805933A (pt) 1989-08-01
JPH01295165A (ja) 1989-11-28
DK582888D0 (da) 1988-10-20
NO884705D0 (no) 1988-10-21
KR890006828A (ko) 1989-06-16

Similar Documents

Publication Publication Date Title
US5089391A (en) Threshold ligand-receptor assay
Avrameas Amplification systems in immunoenzymatic techniques
EP0093613B1 (de) Gleichzeitiges heterogenes Immuntest-Eichungsverfahren, Vorrichtung und diagnostischer Testsatz
IE920778A1 (en) Method for specific binding assays using a releasable ligand
JPH02138869A (ja) 抗原検定法
US5935780A (en) Method for the qualitative or/and quantitative detection of an analyte
CA2446246A1 (en) Systems and methods for detection of analytes in biological fluids
US4637985A (en) Assay processes and materials therefor
US5783453A (en) Non-separation specific binding chemiluminescent assay
US6225043B1 (en) Separation and analysis
AU650503B2 (en) Amplified heterogeneous chemiluminescent immunoassay
AU645491B2 (en) Catalyzed reporter deposition
EP0313274A1 (de) Enzymatisches Bestimmungsverfahren
US5434054A (en) Devices for determining hydrolase activity through its hydrolytic release of an immobilized indicator enzyme
Lin et al. Chemiluminescent flow injection determination of alkaline phosphatase and its applications to enzyme immunoassays
EP0886754B1 (de) Nicht-kompetitiver immunoassay mit blockierung von freien bindungsstellen auf der festen phase
JP3282129B2 (ja) 固相非分離酵素分析
JP3684454B2 (ja) 沈殿可能な固相を用いる不均一系イムノアッセイ
JP4455688B2 (ja) 分析物遊離段階を可能にするアッセイ用表面
US5391483A (en) Ligand analogs for immunoassays derived from dicarboxylic acid oxidation products
CA2013214C (en) Catalyzed reporter deposition
JPH02275360A (ja) 酵素触媒作用の抑制による磁気イムノアッセイにおける信号の増強
CN117871851A (zh) 一种检测中药中噻虫嗪含量的免疫分析方法及免疫试剂盒
JPS61249399A (ja) ミクロペルオキシダーゼを用いる尿酸診断アッセイ
Diamandis et al. MC-1 A new generation of time-resolved fluoroimmunoassays with europium chelates as labels

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL SE

17P Request for examination filed

Effective date: 19891026

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: KINGS COLLEGE LONDON

17Q First examination report despatched

Effective date: 19921210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19930806

18W Application withdrawn

Withdrawal date: 19931013